The two blockbusters have made a big difference in bladder cancer survival, but will their chemistry hold up when tested in other types?

Dr. Matthew Galsky spoke with CURE about the KEYNOTE-B15 trial results and their potential impact on muscle-invasive bladder cancer care. At the 2026 ASCO Genitourinary Cancers Symposium, the ...

Researchers at Fondazione Policlinico Universitario Agostino Gemelli IRCCS have developed a promising machine learning algorithm capable of predicting survival and cause of death for patients with ...

KEYNOTE-B15 compared perioperative enfortumab vedotin plus pembrolizumab against neoadjuvant cisplatin-based chemotherapy in cisplatin-eligible MIBC, using event-free survival as the primary endpoint.

To further complicate clinicians’ treatment decisions, Padcev-Keytruda has become the new standard of care in first-line metastatic bladder cancer, raising the possibility that some physicians might ...

Investigators sought to determine if the gemcitabine intravesical system plus intravenous cetrelimab could improve survival for patients with muscle-invasive bladder cancer who did not receive radical ...

Add Yahoo as a preferred source to see more of our stories on Google. A new treatment for advanced bladder cancer which doubles survival time has been approved for NHS use. The treatment for advanced ...

Approximately 40% of patients with muscle-invasive bladder cancer achieve a clinical complete response after neoadjuvant ...

The FDA has acknowledged receipt of the supplemental Biologics License Application (sBLA) for nogapendekin alfa inbakicept-pmln (Anktiva) plus Bacillus Calmette-Guérin (BCG) in BCG-unresponsive ...

A retrospective cohort study suggested that people with color blindness may have a higher risk of mortality from bladder cancer compared with those who can see colors. The researchers hypothesized ...

CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced treatment with ANKTIVA® (nogapendekin alfa inbakicept-pmln) plus Bacillus ...

People with color vision deficiency -- commonly known as color blindness -- may have a higher risk of mortality from bladder cancer compared with those who can see colors, a retrospective cohort study ...